Using Genetic Tests to Predict Anthracycline Cardiotoxicity
10:13 EDT 2 Aug 2012 | Medscape
Dr. Maurie Markman looks at data from the Children's Oncology Group suggesting that genetic polymorphisms can predict anthracycline-related cardiomyopathy risk even after low doses of the drug. Medscape Hematology-Oncology
Original Article: Using Genetic Tests to Predict Anthracycline Cardiotoxicity
More From BioPortfolio on "Using Genetic Tests to Predict Anthracycline Cardiotoxicity"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
